Physician profile
Sherry E Shuman
NPI 1487767257
$2,411.60
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $790 · 2021: $252 · 2022: $16.54.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.69 | 2019-2022 | |
| Amgen INC. | $439.15 | 2019-2021 | |
| Ucb, INC. | $247.15 | 2019-2021 | |
| Pfizer INC. | $189.61 | 2019-2021 | |
| Celgene Corporation | $174.52 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $139.90 | 2019-2020 | |
| Genentech USA, INC. | $110.93 | 2019-2020 | |
| Janssen Biotech, INC. | $110.91 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $106.26 | 2019-2020 | |
| Lilly USA, LLC | $101.90 | 2019-2020 | |
| Glaxosmithkline, LLC. | $76.16 | 2019-2020 | |
| Astellas Pharma US INC | $62.74 | 2019 | |
| Genzyme Corporation | $61.77 | 2019 | |
| Novo Nordisk INC | $31.97 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.29 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.87 | 2019 | |
| Amarin Pharma, INC. | $13.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.72 | 2019 | |
| Merck Sharp & Dohme LLC | $12.25 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Shuman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.